Making cancer cells visible during surgery
Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery.
DID YOU KNOW?
1 in 4 people with breast cancer require repeat surgeries
We use fluorescence to improve patient outcomes.
Complete removal of cancerous tumor tissue and lymph nodes is the hallmark of a successful surgery. However, surgeons have limited insight into the success of surgery while in the operating room, resulting in increased risk of cancer recurrence and a high rate of repeat surgeries.
With Integro’s fluorescent imaging agent, LS301, surgeons can easily see the amount and location of cancer cells and differentiate between healthy and cancerous tissue during surgery.
Meet Scientific Visionary Dr. Samuel Achilefu
The inventor of Integro’s revolutionary technologies is a pioneering expert in the design and use of fluorescent molecules to improve cancer imaging.
Our Focus on Women’s Health
Every year in the US, 255,000 women are diagnosed with breast cancer and 110,000 with gynecological cancers. Integro’s product pipeline is focused on advancing its cancer-targeting imaging agent for use in breast cancer (leading indication) and gynecological cancers, including ovarian, cervix, uterine, and endometrial cancers. Integro Theranostics is committed to improving the outcome of surgeries in cancers that primarily affect women.
DID YOU KNOW?
Black women are 41% more likely to die from breast cancer compared to White women
Committed to Addressing Health Disparities
Our product development priorities are informed by our commitment to improving disparities in cancer treatment and patient outcomes. Inadequate health insurance, poor access to high-quality detection and treatment, and lack of diversity in clinical trials are just some of the myriad of factors that contribute to cancer health disparities. Integro is committed to developing products that are accessible to all patients and in establishing partnerships to pursue cancer health equity.
-
Black people are more likely to die from most cancers than any other racial or ethnic group. Giaquinto et al. reported that Black women are twice as likely to die from endometrial cancer and 41% more likely to die from breast cancer compared to white women in the US despite similar incidence rates. LS301 could provide an effective strategy for detecting and removing even the most aggressive type of breast cancer, triple negative breast cancer, which is twice as likely to be diagnosed in Black women.
-
Many minority populations are significantly underrepresented in cancer clinical trials, with these racial and ethnic groups also experiencing disparities in cancer care and outcomes. A study evaluating racial and ethnic representation in the 230 clinical trials that supported FDA oncology drug approvals from 2008-2018 found that only 3.1% of clinical trial participants were Black (Blacks represent 13.5% of the US population) and only 6.1% were Hispanic (Hispanics represent 18.5% of the US population). Integro Theranostics is committed to forging partnerships that will help to engage more minority participants in LS301 clinical trials.